First Midwest Bank Trust Division decreased its holdings in Dermira Inc (NASDAQ:DERM) by 20.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 165,701 shares of the biopharmaceutical company’s stock after selling 43,098 shares during the period. First Midwest Bank Trust Division’s holdings in Dermira were worth $1,584,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Bank of America Corp DE grew its position in Dermira by 469.9% during the 4th quarter. Bank of America Corp DE now owns 2,172,328 shares of the biopharmaceutical company’s stock worth $15,619,000 after acquiring an additional 1,791,178 shares during the last quarter. Vivo Capital LLC bought a new stake in Dermira during the 1st quarter worth $9,485,000. Rhenman & Partners Asset Management AB bought a new stake in Dermira during the 1st quarter worth $6,779,000. Candriam Luxembourg S.C.A. bought a new stake in Dermira during the 1st quarter worth $4,743,000. Finally, Jacobs Levy Equity Management Inc. grew its position in Dermira by 68.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 763,590 shares of the biopharmaceutical company’s stock worth $10,347,000 after acquiring an additional 310,551 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.
A number of equities research analysts recently weighed in on the company. Mizuho assumed coverage on Sabre in a research report on Thursday, June 6th. They set a “buy” rating and a $25.00 price objective on the stock. Cantor Fitzgerald restated a “hold” rating and set a $8.00 price objective on shares of Pacific Biosciences of California in a research report on Friday, May 3rd. BidaskClub downgraded Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. HC Wainwright set a $31.00 target price on Kura Oncology and gave the stock a “buy” rating in a report on Wednesday, May 8th. Finally, Zacks Investment Research downgraded Haynes International from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Dermira presently has a consensus rating of “Buy” and an average price target of $17.97.
Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.39). The business had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.63 million. Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. On average, equities analysts predict that Dermira Inc will post -5.2 EPS for the current year.
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Further Reading: What is a Real Estate Investment Trust (REIT)?
Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.